Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.05.008Source: DataRank Database

Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis is a research paper published in Journal of Cystic Fibrosis (2021). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: bronzeTopics (40)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Kevin J. Ryan ORCID,Hector Gutierrez ORCID,Luz Helena Gutierrez Sanchez ORCID,Janaina Nogueira Anderson ORCID,Edward P. Acosta

Live enrichment

PubMed:34130909 PMC:PMC8665941

NHLBI NIH HHS

Grant: K23 HL143167

NIDDK NIH HHS

Grant: P30 DK072482

National Institutes of Health

Grant: 7K23HL143167-05

Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients

Cystic Fibrosis Foundation

National Heart Lung and Blood Institute

bronzeLicense: Elsevier Non-Commercial

publisherhttp://www.cysticfibrosisjournal.com/article/S1569199321001594/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199321001594?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199321001594?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8665941

https://doi.org/10.1016/j.jcf.2021.05.008

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansCystic FibrosisAminophenolsTacrolimusPyrazolesPyridinesPyrrolidinesIndolesQuinolonesImmunosuppressive AgentsDrug Therapy, CombinationLiver TransplantationAdolescentFemaleBenzodioxolesChloride Channel Agonists

Keywords

Liver transplantationCytochrome p450Tacrolimusdrug interactionCftrIvacaftorTezacaftorElexacaftorIndolesPyrrolidinesAdolescentCystic FibrosisPyridinesQuinolonesAminophenolsHumansPyrazolesDrug Therapy, CombinationFemaleBenzodioxolesChloride Channel AgonistsImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good health